



Press release 2021-04-23

The Patent and Market Court of Appeal issues judgement confirming C-RAD's entitlement to Beamocular's invention

The Patent and Market Court of Appeal at the Svea Court of Appeal partly confirms the judgment of the Patent and Market Court of 26 July 2019, which gave C-RAD the right to the invention described in the patent application entitled “Ionizing radiation detecting device”. The judgment from the Patent and Market Court of Appeal gives C-RAD the right to 50 percent of the invention as certain minor parts of the invention originates from Beamocular, a company in bankruptcy. C-RAD sued Beamocular in May 2017. The judgment of the Patent and Market Court of Appeal cannot be appealed. Both parties will carry their own legal cost.

The disputed invention is closely related to the research and development of C-RAD's image detector called 'Gemini'. This product is not commercialized and all development and operations around this product ceased in December 2019 in favor of full focus on the company's positioning products, whereas this ruling has no impact on C-RAD's current operations.

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 12:20 CET on April 23rd 2021.